目的通过检测口腔癌皮下移植瘤小鼠小肠中代谢物和代谢通路的变化,分析过表达miR-181a-5p对皮下移植瘤小鼠小肠中代谢物和代谢物组的影响。方法实验分为3组,空白对照(Control)组、阴性对照(negative control,NC)组以及实验(over express...目的通过检测口腔癌皮下移植瘤小鼠小肠中代谢物和代谢通路的变化,分析过表达miR-181a-5p对皮下移植瘤小鼠小肠中代谢物和代谢物组的影响。方法实验分为3组,空白对照(Control)组、阴性对照(negative control,NC)组以及实验(over expression of miR-181a-5p,OE)组。将不同组别处理后的细胞混悬液,通过皮下注射到M-NSG重度免疫缺陷雌性小鼠右侧腹股沟中上部,构建成口腔癌皮下移植瘤小鼠模型。按时记录小鼠体重变化,对小鼠小肠组织进行HE染色,观察各组病理变化。采用超高效液相色谱-串联飞行时间质谱联用仪和串联Orbitrap质谱联用仪检测NC组、OE组和Control组小鼠小肠中的代谢物,使用XCMS预分析原始数据,质量评价样本数据,鉴定Control组与NC组、NC组与OE组的差异代谢物,进行KEGG富集分析获取差异代谢通路。结果Control组和NC组小肠组织中共鉴定出170种差异代谢物。代谢物富集的显著性信号通路包括胆碱代谢、丙氨酸、天冬氨酸和谷氨酸代谢、γ-氨基丁酸(GABA)神经突触代谢、甘油磷脂代谢、环磷酸腺苷(cAMP)信号通路代谢、癌症中心碳代谢以及烟酸和烟碱胺代谢通路。NC组和OE组相比,小鼠小肠中检测到VIP(variable importance in the projection)>2的差异代谢物有16种,显著性差异代谢物包括甘油磷酰胆碱、棕榈酸、3-羟基丁酰肉碱、β-羟丁酸等。代谢物富集到的显著性差异通路为胆碱代谢通路。结论口腔癌皮下移植瘤可引起小鼠小肠的代谢物发生变化,主要改变了小肠中与能量代谢相关的代谢物。过表达miR-181a-5p影响口腔癌皮下移植瘤小鼠小肠代谢物,代谢物富集通路为胆碱代谢通路。展开更多
Background:Glioblastoma remains a highly invasive primary brain malignancy with an undesirable prognosis.Growing evidence has shed light on the importance of microRNAs(miRs),as small non-coding RNAs,in tumor developme...Background:Glioblastoma remains a highly invasive primary brain malignancy with an undesirable prognosis.Growing evidence has shed light on the importance of microRNAs(miRs),as small non-coding RNAs,in tumor development and progression.The present study leverages the in-silico and in-vitro techniques to investigate the significance of hsa-miR-181a-5p and the underlying hsa-miR-181a-5p-meidated signaling pathway in glioblastoma development.Methods:Bioinformatic studies were performed on GSE158284,GSE108474(REMBRANDT study),TCGA-GTEx,CCLE,GeneMANIA,Reactome,WikiPathways,KEGG,miRDB,and microT-CDS to identify the significance of hsa-miR-181a-5p and its underlying target.Afterward,the U373 cell line was selected and transfected with hsa-miR-181a-5p mimics,and the cell viability,clonogenicity,migration,mRNA expression,apoptosis,and cell cycle were studied using the MTT assay,colony formation test,migration assay,qRT-PCR,andflow cytometry respectively.Results:hsa-miR-181a-5p expression is decreased in glioblastoma samples.The in-silico results have shown that hsa-miR-181a-5p could regulate the MAPK pathway by targeting AKT3.The experimental assays have shown that hsa-miR-181a-5p decreases the migration of glioblastoma cells,arrests the cell cycle,and increases the apoptosis rate.Besides downregulating MMP9 and upregulating BAX,hsa-miR-181a-5p downregulates MET,MAP2K1,MAPK1,MAPK3,and AKT3 expression in U373 cells.The in-vitro results were consistent with in-silico results regarding the regulatory effect of hsa-miR-181a-5p on the MAPK pathway,leading to tumor suppression in glioblastoma.Conclusions:hsa-miR-181a-5p inhibits glioblastoma development partially by regulating the signaling factors of the MAPK pathway.展开更多
文摘目的通过检测口腔癌皮下移植瘤小鼠小肠中代谢物和代谢通路的变化,分析过表达miR-181a-5p对皮下移植瘤小鼠小肠中代谢物和代谢物组的影响。方法实验分为3组,空白对照(Control)组、阴性对照(negative control,NC)组以及实验(over expression of miR-181a-5p,OE)组。将不同组别处理后的细胞混悬液,通过皮下注射到M-NSG重度免疫缺陷雌性小鼠右侧腹股沟中上部,构建成口腔癌皮下移植瘤小鼠模型。按时记录小鼠体重变化,对小鼠小肠组织进行HE染色,观察各组病理变化。采用超高效液相色谱-串联飞行时间质谱联用仪和串联Orbitrap质谱联用仪检测NC组、OE组和Control组小鼠小肠中的代谢物,使用XCMS预分析原始数据,质量评价样本数据,鉴定Control组与NC组、NC组与OE组的差异代谢物,进行KEGG富集分析获取差异代谢通路。结果Control组和NC组小肠组织中共鉴定出170种差异代谢物。代谢物富集的显著性信号通路包括胆碱代谢、丙氨酸、天冬氨酸和谷氨酸代谢、γ-氨基丁酸(GABA)神经突触代谢、甘油磷脂代谢、环磷酸腺苷(cAMP)信号通路代谢、癌症中心碳代谢以及烟酸和烟碱胺代谢通路。NC组和OE组相比,小鼠小肠中检测到VIP(variable importance in the projection)>2的差异代谢物有16种,显著性差异代谢物包括甘油磷酰胆碱、棕榈酸、3-羟基丁酰肉碱、β-羟丁酸等。代谢物富集到的显著性差异通路为胆碱代谢通路。结论口腔癌皮下移植瘤可引起小鼠小肠的代谢物发生变化,主要改变了小肠中与能量代谢相关的代谢物。过表达miR-181a-5p影响口腔癌皮下移植瘤小鼠小肠代谢物,代谢物富集通路为胆碱代谢通路。
文摘Background:Glioblastoma remains a highly invasive primary brain malignancy with an undesirable prognosis.Growing evidence has shed light on the importance of microRNAs(miRs),as small non-coding RNAs,in tumor development and progression.The present study leverages the in-silico and in-vitro techniques to investigate the significance of hsa-miR-181a-5p and the underlying hsa-miR-181a-5p-meidated signaling pathway in glioblastoma development.Methods:Bioinformatic studies were performed on GSE158284,GSE108474(REMBRANDT study),TCGA-GTEx,CCLE,GeneMANIA,Reactome,WikiPathways,KEGG,miRDB,and microT-CDS to identify the significance of hsa-miR-181a-5p and its underlying target.Afterward,the U373 cell line was selected and transfected with hsa-miR-181a-5p mimics,and the cell viability,clonogenicity,migration,mRNA expression,apoptosis,and cell cycle were studied using the MTT assay,colony formation test,migration assay,qRT-PCR,andflow cytometry respectively.Results:hsa-miR-181a-5p expression is decreased in glioblastoma samples.The in-silico results have shown that hsa-miR-181a-5p could regulate the MAPK pathway by targeting AKT3.The experimental assays have shown that hsa-miR-181a-5p decreases the migration of glioblastoma cells,arrests the cell cycle,and increases the apoptosis rate.Besides downregulating MMP9 and upregulating BAX,hsa-miR-181a-5p downregulates MET,MAP2K1,MAPK1,MAPK3,and AKT3 expression in U373 cells.The in-vitro results were consistent with in-silico results regarding the regulatory effect of hsa-miR-181a-5p on the MAPK pathway,leading to tumor suppression in glioblastoma.Conclusions:hsa-miR-181a-5p inhibits glioblastoma development partially by regulating the signaling factors of the MAPK pathway.
